US45337C1027 - Common Stock
54.7 -0.48 (-0.87%)
After market: 54.7 0 (0%)
NASDAQ:INCY (12/8/2023, 7:00:02 PM)After market: 54.7 0 (0%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,324 full-time employees. The firm also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. The company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.
1801 Augustine Cut-Off
Wilmington DELAWARE 19803
CEO: Herve Hoppenot
Despite its impressive fundamentals, INCYTE CORP (NASDAQ:INCY) remains undervalued.
Investors should take note ofINCYTE CORP (NASDAQ:INCY), a growth stock that remains attractively priced.
Goldman Sachs downgraded Incyte (INCY) due to uncertainty surrounding the lifecycle management of its drug Jakafi ahead of its loss of market exclusivity. Read more here.
Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year.
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.
Here you can normally see the latest stock twits on INCY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.